SLC5A2 and chronic kidney disease: Moreover, they are indicated for slowing the progression of chronic kidney disease (CKD) and preventing major cardiovascular events in patients with diabetes mellitus or albuminuria (Class I recommendation for treating adults with CKD using an SGLT2 inhibitor for an estimated glomerular filtration rate of ≥20 mL/min per 1.73 m2 and a urine albumin-to-creatinine ratio of ≥200 mg/g) [128].